Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

NCT07446998 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity & Overweight
Mobility Disability
HOMA-IR

Interventions

DRUG: Enobosarm
DRUG: Semaglutide (Wegovy) weekly injection

Sponsor

Veru Inc.